humacyte.com
Get leads like Humacyte — and thousands more
Build targeted lists by tech stack, and more
Humacyte: Building Life from Lab to Market
The biotech veteran with $692M in funding and a mission to bioengineer tissues
Humacyte isn't just building websites; they're bioengineering the future of medicine. With $692.9M in funding, this is a company betting big on regenerative medicine. But the real story isn't just the science—it's the execution gap between a $1.2M revenue reality and a billion-dollar vision.
"In biotech, funding isn't a milestone—it's oxygen. Humacyte has enough to breathe for years, but revenue is the only metric that ultimately matters."
The Manufacturing Moat
Unlike typical biotech startups, Humacyte's 257 employees aren't just coding—they're manufacturing. Their Human Acellular Vessel (HAV) represents a shift from pharma's chemical approach to engineering living tissue. The real barrier to entry isn't just IP; it's the capital-intensive infrastructure to scale bioengineering from lab bench to clinical supply chain.
The Revenue Paradox
Here's the tension: $1.2M in revenue against $692.9M in funding. That's not a failure—it's a strategic choice. Humacyte is in the 'capital burn before revenue bloom' phase typical of advanced biotech. The question isn't about current ARR; it's about whether their bioengineered vessels can achieve regulatory approval and commercial scale before the runway ends. With 257 employees, they're sized for clinical trials, not mass production yet.
The leadership team reads like a biotech dream team: Laura Niklason (Founder, President & CEO) brings scientific credibility, while Dale Sander (CFO) and Gary Morris (VP Finance) manage the delicate balance between R&D burn and financial discipline. Juliana Blum's role in Corporate Development suggests they're already thinking beyond the lab—partnerships, licensing, and strategic alliances that could accelerate commercialization.
- Bioengineered tissue platform with potential across vascular, cardiac, and organ applications
- Clinical-stage company with FDA pathways already in motion
- Capital-efficient model: $692M raised vs. 257 employees suggests disciplined spending
- Leadership team balances scientific rigor with financial acumen
The Billion-Dollar Bet
Humacyte represents the hardest type of startup: capital-intensive, science-heavy, and regulation-bound. But if they succeed, they don't just build software—they rebuild human tissue. That's a moat no SaaS company can replicate.
What tech stack does Humacyte use?
How much traffic does Humacyte get?
No analytics data available
Get traffic analytics, rankings, backlinks, and keyword data.
What is Humacyte's revenue?
Who works at Humacyte?
Loading leads...
What do customers think of Humacyte?
No Trustpilot reviews available for this company.
Frequently Asked Questions about Humacyte
What is Humacyte's Revenue?
How fast is Humacyte growing?
What technologies does Humacyte use?
Who are Humacyte's competitors?
Export Data
Unlock all exports
Download CSVs, JSONs & full reports
Export humacyte.com Data
Download the complete tech stack, analytics, leads, and company data for humacyte.com in JSON or CSV format. Use it for your sales pipeline, competitive analysis, or research.
Raw JSON Data
Click "Show" to view the raw API response data
About humacyte.com
Company Overview
Technology Stack
humacyte.com uses 14 technologies across their website including Font Awesome, Adobe Fonts, PHP, WordPress, and more.
Fonts
Font Awesome, Adobe Fonts, Google Fonts
Programming Languages
PHP
CMS
WordPress
CDN
unpkg, jsDelivr
Analytics & Marketing
Google Analytics
Web Standards
Twitter Cards, PWA
Frequently Asked Questions
What is humacyte.com?
What technologies does humacyte.com use?
Related Searches
This page provides publicly available information about humacyte.com. Data is collected from various public sources and may not always be up to date. For the most accurate information, please visit humacyte.com directly at https://humacyte.com.